Patents by Inventor Isao Nagaoka
Isao Nagaoka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10195271Abstract: The present invention addresses the problem of providing an antibody titer-increasing agent, such as an adjuvant, capable of sustaining an effect achieved by, for example, vaccination, which is an antibody titer-increasing agent such as an adjuvant that is safe, convenient and economical and can be easily taken irrespective of age, and a method for manufacturing the same. A method for increasing an antibody titer and a method for enhancing the effect of a vaccine, each method comprising using Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 or a culture thereof; and an antibody titer-increasing agent such as an adjuvant that comprises Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 or a culture thereof.Type: GrantFiled: August 26, 2014Date of Patent: February 5, 2019Assignee: Meiji Co., Ltd.Inventors: Seiya Makino, Jun Henmi, Hiroshi Kano, Yukio Asami, Shuji Ikegami, Hiroyuki Itou, Yoshio Suzuki, Sachio Kawai, Keisuke Sawaki, Ko Okumura, Isao Nagaoka, Kazuyoshi Takeda
-
Publication number: 20160206733Abstract: The present invention addresses the problem of providing an antibody titer-increasing agent, such as an adjuvant, capable of sustaining an effect achieved by, for example, vaccination, which is an antibody titer-increasing agent such as an adjuvant that is safe, convenient and economical and can be easily taken irrespective of age, and a method for manufacturing the same. A method for increasing an antibody titer and a method for enhancing the effect of a vaccine, each method comprising using Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 or a culture thereof; and an antibody titer-increasing agent such as an adjuvant that comprises Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 or a culture thereof.Type: ApplicationFiled: August 26, 2014Publication date: July 21, 2016Applicant: Meiji Co., Ltd.Inventors: Seiya Makino, Jun Henmi, Hiroshi Kano, Yukio Asami, Shuji Ikegami, Hiroyuki Itou, Yoshio Suzuki, Sachio Kawai, Keisuke Sawaki, Yasushi Okumura, Isao Nagaoka, Kazuyoshi Takeda
-
Patent number: 8242082Abstract: The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient.Type: GrantFiled: April 16, 2008Date of Patent: August 14, 2012Assignee: Seikagaku CorporationInventors: Isao Nagaoka, Daiju Okuda, Shin Yomogida, Hiroshi Tamura
-
Publication number: 20090149632Abstract: The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient.Type: ApplicationFiled: April 16, 2008Publication date: June 11, 2009Inventors: Isao Nagaoka, Daiju Okuda, Shin Yomogida, Hiroshi Tamura
-
Patent number: 7452856Abstract: The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient.Type: GrantFiled: March 29, 2005Date of Patent: November 18, 2008Assignees: Seikagaku Corporation, Juntendo UniversityInventors: Isao Nagaoka, Daiju Okuda, Shin Yomogida, Hiroshi Tamura
-
Publication number: 20060009374Abstract: The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID NO: 1): X01 X02 X03 X03 X04 X02 X03 X03 X05 X04 X03 X04 X02 X01 X03 X02 X05 X03 (wherein X01 represents a cationic amino acid residue or a polar uncharged amino acid residue, X02 represents a non-polar amino acid residue, X03 represents a cationic amino acid residue, X04 represents a non-polar amino acid residue or a cationic amino acid residue, and X05 represents a non-polar amino acid residue or a polar uncharged amino acid residue). Each of the antibacterial agent, lipopolysaccharide-cell-binding inhibitor, and drug (e.g., bacterial-infection-treating agent or endotoxin-shock suppressant) contains the peptide as an active ingredient.Type: ApplicationFiled: March 29, 2005Publication date: January 12, 2006Inventors: Isao Nagaoka, Daiju Okuda, Shin Yomogida, Hiroshi Tamura
-
Patent number: 6627621Abstract: Glucosamine salts are effective for the inhibition of neutrophil functions, and hence, are useful for the prevention and/or treatment of diseases, caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, such as respiratory disease syndrome and adult respiratory disease syndrome. Use of glucosamine salts can, therefore, provide neutrophil function inhibitors, preventives and/or remedies for diseases caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, and also methods for the prevention and/or treatment of such diseases.Type: GrantFiled: July 18, 2001Date of Patent: September 30, 2003Assignee: Dainichieseika Color & Chemicals Mfg. Co., Ltd.Inventors: Isao Nagaoka, Koji Sakamoto
-
Publication number: 20020128230Abstract: Glucosamine salts are effective for the inhibition of neutrophil functions, and hence, are useful for the prevention and/or treatment of diseases, caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, such as respiratory disease syndrome and adult respiratory disease syndrome. Use of glucosamine salts can, therefore, provide neutrophil function inhibitors, preventives and/or remedies for diseases caused as a result of an excessive extracellular release of active oxygen and antibiotic proteins by neutrophils, and also methods for the prevention and/or treatment of such diseases.Type: ApplicationFiled: July 18, 2001Publication date: September 12, 2002Applicant: Koyo Chemical Co., Ltd.Inventors: Isao Nagaoka, Koji Sakamoto
-
Patent number: 4542578Abstract: Mutually spaced apart TCO film portions are formed on a glass substrate. An amorphous silicon film of PIN junction type is formed to cover these TCO film portions, and an aluminum film is formed thereon. The aluminum film in the vicinity of the gap between adjacent TCO film portions is removed by means of a laser beam, and the amorphous silicon film is removed by reactive plasma etching using the aluminum film as a mask to thereby expose portions of the TCO film. An aluminum-titanium film is formed over the aluminum film and the exposed portions of the TCO film. The aluminum-titanium film is separated by means of a laser beam to form a plurality of photoelectric converting regions. The photoelectric converting regions thus formed on the glass substrate are connected in series.Type: GrantFiled: March 15, 1984Date of Patent: September 24, 1985Assignee: Sanyo Electric Co., Ltd.Inventors: Masaru Yamano, Isao Nagaoka, Yukinori Kuwano, Hiroshi Kawada, Souichi Sakai
-
Patent number: 4082817Abstract: A process for producing a maleic anhydride adduct of high molecular weight 1,2-polybutadiene by contacting with heat maleic anhydride with high molecular weight 1,2-polybutadiene in the absence of a radical initiator in a halogenated aromatic hydrocarbon solvent. The adduct obtained by this process has a high molecular weight of more than 10,000 and is quite free from gel. Said process enables the addition of maleic anhydride in any desired proportion.Type: GrantFiled: March 29, 1976Date of Patent: April 4, 1978Assignee: Japan Synthetic Rubber Co., Ltd.Inventors: Fumitake Imaizumi, Isao Nagaoka, Mitsuo Kurokawa, Koei Komatsu
-
Patent number: 4075096Abstract: A suction device for an oil separation tank mounted on a floating body comprises a liquid piping structure for transporting floating oil from the oil separation tank into a storage tank and a vacuum piping structure for always retaining floating oil in the oil separation tank at a suction state, and may automatically control an intermittent suction operation.Type: GrantFiled: September 16, 1976Date of Patent: February 21, 1978Assignee: Bridgestone Tire Company LimitedInventors: Hiroshi Kawakami, Yukio Tsukagawa, Isao Nagaoka
-
Patent number: 4049170Abstract: A device for pulling up and paying out an oil boom comprises a structural frame, a pair of end pulleys horizontally journaled on the frame, an endless belt engaged with the end pulleys and having a plurality of engaging projections for oil boom and a pusher member for slightly urging the oil boom against the endless belt, the pusher member being resiliently supported by a supporting member with a proper distance held between the bottom portion of the pusher member and the upper surface of the endless belt.Type: GrantFiled: April 23, 1976Date of Patent: September 20, 1977Assignee: Bridgestone Tire Company LimitedInventors: Hiroshi Kawakami, Isao Nagaoka, Yukio Tsukagawa
-
Patent number: 4023973Abstract: A photosensitive composition comprising (1) a maleic anhydride adduct of 1,2-polybutadiene having a molecular weight of 10,000 or higher, (2) at least one photosensitizer and/or at least one photosensitive crosslinking agent, and, if necessary, (3) at least one acrylic monomer. This composition can be developed with water or a polar solvent such as an alcohol, and its layer formed on a support provides a printing plate. When the acrylic monomer is contained, the composition is suitable for use in flexographic printing.Type: GrantFiled: April 17, 1975Date of Patent: May 17, 1977Assignee: Japan Synthetic Rubber Co., Ltd.Inventors: Fumitake Imaizumi, Isao Nagaoka, Mitsuo Kurokawa, Koei Komatsu, Yasuyuki Takimoto, Hidefumi Kusuda
-
Patent number: 3931136Abstract: High molecular weight cis-1,4-polyisoprene is produced by contacting isoprene with a catalyst formed by admixing (A) a titanium tetrachloride, (B) a trihydrocarbylaluminum and (C) a beta-diketone. The activity of this ternary catalyst is not adversely affected by such impurities as cyclopentadiene that are contained in the feed stock isoprene.Type: GrantFiled: May 23, 1974Date of Patent: January 6, 1976Assignee: Japan Synthetic Rubber Co., Ltd.Inventors: Kan Mori, Hiroharu Ikeda, Isao Nagaoka, Tooru Shibata, Sigeo Kawatani, Tatsuhiko Kikuchi